Investor Overview

Corporate Profile
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.22
Change (%) Stock is Up 0.05 (1.58%)
Volume14,509
Data as of 09/29/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
09/29/16Histogenics Corporation Closes $30.0 Million Private Placement
WALTHAM, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the closing of its previously disclosed $30.0 million private placement of common stock, Series A Convertible Preferred Stock and warrants pursuant to a securities purchase agreement.  The private placement was led by new healthcare dedicated institutional investor... 
Printer Friendly Version
09/26/16Histogenics Corporation to Present at the 2016 Cell & Gene Meeting on the Mesa
WALTHAM, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will be presenting a corporate overview during the meeting’s Partnering Forum on Wednesday, October 5, 2016, at 5:15 pm PDT. The conference will be held October 5-7 at the Estancia La Jolla Ho... 
Printer Friendly Version
09/16/16Histogenics Corporation Announces $30.0 Million Private Placement
WALTHAM, Mass., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that it has entered into a definitive securities purchase agreement to raise approximately $30.0 million in a private placement of common stock, Series A Convertible Preferred Stock and warrants exercisable for common stock.  The private placement is being led by n... 
Printer Friendly Version
08/31/16Histogenics Corporation to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
WALTHAM, Mass., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 18th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at 11:40 AM EDT.  The conference is sponsored by H.C. Wainwright & Co., LLC.,... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
10/15/16 5:15 p.m. PT
Histogenics Corp Other Corporate
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.